DBV Technologies delays peanut patch submission to third quarter
The biotech company reported a second-quarter net loss of $50.4 million as it shifted its regulatory timeline.
DBV Technologies (DBVT), the biotechnology company, delayed the Biologics License Application submission for its VIASKIN Peanut Patch in children aged 4-7 years from the first half of 2026 to the third quarter of 2026.
The shift in the regulatory timeline coincided with a widening loss as the company advanced its clinical pipeline. DBV Technologies reported a net loss of $50.4 million for the second quarter of 2026, compared with a loss of $41.9 million in the same period in 2025. For the first half of 2026, the net loss rose to $98.0 million from $69.0 million during the first half of 2025.
Operating income for the second quarter fell to $0.7 million from $1.5 million a year earlier, due to lower French research tax credit accruals. While research and development expenses decreased to $31.2 million from $33.7 million in the second quarter of 2025, selling, general and administrative expenses rose by $11.2 million over the same period.
Clinical activity continued with the initiation of the THRIVE study in infants aged 6 through 12 months during the second quarter. Additionally, the company closed recruitment for the COMFORT Toddlers supplemental safety study.
Cash and cash equivalents ended the quarter at $174.9 million, down from $229 million as of March 31, 2026. Net cash used in operating and investing activities for the first half of 2026 increased to $102.6 million, up from $54.0 million for the first half of 2025.
Despite the increased cash burn, the company extended its cash runway into the third quarter of 2027, an improvement over the second quarter of 2027 forecast provided in the prior quarter. Net financial income for the first half of 2026 was $0.9 million, reversing a net financial expense of $1.1 million in the first half of 2025.